Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.43
+0.48 (8.07%)
At close: Apr 17, 2026, 4:00 PM EDT
6.40
-0.03 (-0.47%)
After-hours: Apr 17, 2026, 7:09 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.85 billion as of April 17, 2026. Its market cap has increased by 612.28% in one year.
Market Cap
1.85B
Enterprise Value
1.57B
1-Year Change
612.28%
Ranking
Category
Stock Price
$6.43
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.85B, an increase of 167.54%. That is a compound annual growth rate of 19.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 1.71B | 13.45% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Innoviva | 1.77B |
| Rapport Therapeutics | 1.75B |
| Intellia Therapeutics | 1.74B |
| Nurix Therapeutics | 1.71B |
| Harmony Biosciences Holdings | 1.70B |
| Nuvation Bio | 1.65B |
| Oculis Holding AG | 1.63B |
| Vir Biotechnology | 1.61B |